Retour à la liste des essais cliniquesBreast cancer

HEROES

De-escalation of medical treatments in HER2-positive metastatic breast cancer in case of long-term persistent response and undetectable minimal residual disease assessed by circulating tumor DNA.

Ouvert à Paris depuis le : 07/05/2025
Ouvert à Saint-Cloud depuis le : 07/05/2025
Public cible : Adult
Phase : Phase II

Description de l'essai

To assess the feasibility of therapeutic de-escalation in HER2-positive metastatic breast cancer patients whose disease is controlled after 2 years of maintenance anti-HER2 targeted therapy and who have a negative circulating tumor DNA (ctDNA) test.

Url of the trial

Investigateur principal

DIANA BELLO ROUFAI

Médecin

Contacter